Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIC-1001 and GIC-1002 for Visceral Pain in Healthy Volunteers
NCT02276768Phase 1Completed
- Sponsor
- gIcare Pharma Inc
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trimebutine 3-thiocarbamoylbenzenesulfonate in Visceral pain (5 arms), sponsored by gIcare Pharma Inc. Primary endpoint: Mean visceral pain intensity score following dosing with GIC-1001 375 mg TID at Day 4. Started Oct 2014; status: completed.
02
Drugs
trimebutine 3-thiocarbamoylbenzenesulfonate
03
Conditions
Visceral pain
Beyond the preview
Go deeper on NCT02276768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02276768.